Isturisa denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for isturisa are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Isturisa as Experimental

An experimental or investigational denial from Cigna signals that the plan's medical policy does not recognize Isturisa (osilodrostat) as an established, evidence-based therapy for the condition in your specific clinical scenario. This is a notable denial type for Isturisa because the drug does carry FDA approval for Cushing's disease in adults — a fact that forms the cornerstone of your appeal.

Experimental denials are among the most successfully overturned on external review when the drug in question has a clear regulatory approval status. The appeal pathway is well-defined and your rights are strong.

## Federal Appeal Framework

• FDA approval is your anchor: When a drug has received FDA approval for the indication being treated, an insurer's characterization of it as experimental is directly contestable. The denial letter must explain why the plan's policy departs from the FDA's determination.
• ACA §2719 / ERISA §503: You are entitled to a full internal appeal with a written decision explaining exactly which clinical-evidence standard was applied.
• External review: If the internal appeal fails, escalate to an IRO. Under ACA rules for experimental/investigational denials, IROs apply recognized clinical standards — not just the plan's internal policy. You generally have approximately four months from the denial date to request external review; confirm your exact deadline on the denial notice.
• Expedited option: Available if delay would seriously jeopardize your health.

## Concrete Appeal Process and Timeline

1. File a written internal appeal with Cigna, citing the FDA-approved indication and the applicable endocrinology society guidelines. 2. Demand in writing that Cigna provide the specific clinical evidence standard it applied and a list of the sources it reviewed. 3. If denied internally, immediately file for IRO external review before your deadline expires. 4. IRO decisions are typically rendered within 45 days (standard) or 72 hours (expedited) and are binding on the plan.

## Documentation to Gather

• Diagnosis confirmation: Endocrinology records confirming active Cushing's disease — biochemical testing, imaging, and clinical evaluation documented in the chart.
• FDA-approval evidence: Include the FDA label for Isturisa showing the approved indication (available on the FDA website) directly in your appeal package.
• Guideline support: Reference from the applicable endocrinology professional society (such as the Endocrine Society or Pituitary Society) supporting osilodrostat as a recognized treatment option; obtain the current guideline publication.
• Prescriber medical-necessity letter: A detailed letter from the treating endocrinologist explaining the evidence basis for the prescription, the FDA-approved indication, and the patient's clinical fit.
• Treatment history: Documentation of the clinical course that led to this prescription choice.

## Criteria-Mapping Structure

Obtain Cigna's medical policy for Isturisa and its definition of "experimental/investigational." Then map each criterion the policy lists:

| Policy Criterion | Response with Evidence | |---|---| | FDA approval for the specific indication | [FDA label, approval date, indication language] | | Support in recognized clinical practice guidelines | [Society guideline name, publication year, relevant language] | | Sufficient published evidence of safety and efficacy | [Cite peer-reviewed publications your prescriber identifies] |

Attach all cited documents. A well-mapped appeal that directly addresses each criterion in the plan's own experimental-denial definition gives the IRO a clear basis to overturn.